Ana Cala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Cala has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ana Bilic-Pavlinovic
School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
1 shared publication - Andrija Nekic
Department for Cardiovascular Diseases, University Hospital Center Zagreb, 10000 Zagreb, Croatia
1 shared publication - Borka Pezo-Nikolic
University Hospital Centre Zagreb, Department of Cardiovascular Diseases , Zagreb , Croatia
1 shared publication - Davor Milicic
Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia
1 shared publication - Davor Puljevic
University Hospital Centre Zagreb, Department of Cardiovascular Diseases , Zagreb , Croatia
1 shared publication - Domagoj Kardum
Department for Cardiovascular Diseases, University Hospital Center Zagreb, 10000 Zagreb, Croatia
1 shared publication
Latest Publications
- Open Access
- 7 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 7076
Completely Fluoroless, “Apron-Less” Approach to Supraventricular Tachycardia Ablation Compared to Traditional Fluoroscopy Guided Ablation: Feasibility, Safety and Clinical Outcomes
Background: Catheter ablation is an established first-line treatment for supraventricular tachycardia (SVT). Traditionally, these procedures have been performed under fluoroscopic guidance. The objective of this study was to demonstrate the feasibility and safety of a completely fluoroless approach, as well as to evaluate clinical outcomes. Methods: This retrospective, single-center analysis included two patient cohorts, comprising a total of 400 patients: 200 in the main (fluoroless) group and 200 in the control (fluoroscopy) group. In the main group, ablation was performed using a 3D mapping system and intracardiac echocardiography (ICE) without the use of fluoroscopy and lead aprons. In the control group, procedures were conducted under fluoroscopic guidance. The primary outcomes were feasibility and safety. Secondary outcomes included acute procedural success, defined as non-inducibility of tachycardia, and chronic success, measured as arrhythmia recurrence-free survival during a 6-month follow-up period. Results: Completely fluoroless ablation was successfully performed in all patients in the main group (100%). Procedures were shorter in the fluoroless group (59.0 ± 25.8 min vs. 72.7 ± 34.0 min, p < 0.001), with no difference in acute success rates (100% vs. 100%). No serious complications occurred in the main group, compared to one event in the control group (0 vs. 1.0, p = 0.313). Arrhythmia recurrence rates during follow-up were similar between groups (HR: 0.877, 95% CI: 0.367–2.097, p = 0.769). Conclusions: A completely fluoroless, “apron-less” approach to SVT ablation is feasible, with complication and success rates comparable to the traditional fluoroscopy-guided approach.
- 7 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 7076
Open AccessCompletely Fluoroless, “Apron-Less” Approach to Supraventricular Tachycardia Ablation Compared to Traditional Fluoroscopy Guided Ablation: Feasibility, Safety and Clinical Outcomes
Background: Catheter ablation is an established first-line treatment for supraventricular tachycardia (SVT). Traditionally, these procedures have been performed under fluoroscopic guidance. The objective of this study was to demonstrate the feasibility and safety of a completely fluoroless approach, as well as to evaluate clinical outcomes. Methods: This retrospective, single-center analysis included two patient cohorts, comprising a total of 400 patients: 200 in the main (fluoroless) group and 200 in the control (fluoroscopy) group. In the main group, ablation was performed using a 3D mapping system and intracardiac echocardiography (ICE) without the use of fluoroscopy and lead aprons. In the control group, procedures were conducted under fluoroscopic guidance. The primary outcomes were feasibility and safety. Secondary outcomes included acute procedural success, defined as non-inducibility of tachycardia, and chronic success, measured as arrhythmia recurrence-free survival during a 6-month follow-up period. Results: Completely fluoroless ablation was successfully performed in all patients in the main group (100%). Procedures were shorter in the fluoroless group (59.0 ± 25.8 min vs. 72.7 ± 34.0 min, p < 0.001), with no difference in acute success rates (100% vs. 100%). No serious complications occurred in the main group, compared to one event in the control group (0 vs. 1.0, p = 0.313). Arrhythmia recurrence rates during follow-up were similar between groups (HR: 0.877, 95% CI: 0.367–2.097, p = 0.769). Conclusions: A completely fluoroless, “apron-less” approach to SVT ablation is feasible, with complication and success rates comparable to the traditional fluoroscopy-guided approach.